Unicycive Therapeutics (UNCY) Notes Payables (2020 - 2021)
Unicycive Therapeutics posted quarterly Notes Payables of $3.2 million for Q2 2021, up 109.36% on a QoQ basis from $1.5 million in Q4 2020.
Unicycive Therapeutics (UNCY) has 2 years of Notes Payables data on file, last reported at $3.2 million in Q2 2021.
- For the quarter ending Q2 2021, Notes Payables changed N/A year-over-year to $3.2 million; the trailing twelve-month figure through Jun 2021 stood at $3.2 million (changed N/A YoY), and the FY2020 full-year result was $1.5 million, changed N/A from the prior year.
- Notes Payables for Q2 2021 stood at $3.2 million, up from $1.5 million in the prior quarter.
- Across five years, Notes Payables topped out at $3.2 million in Q2 2021 and bottomed at $1.5 million in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 3.20 Mn |
| Dec 31, 2020 | 1.53 Mn |